The emerging landscape of lncRNAs in diabetic nephropathy

The emerging landscape of lncRNAs in diabetic nephropathy

Xiaoyun He1,2, Chibin Pu3, Chunlin Ou1*, Suxian Zhou2,4*

1Department of Pathology, 2Department of Endocrinology, Xiangya Hospital, Central South University, Changsha 410008, China; 3Department of Gastroenterology, Zhongda Hospital, Southeast University, Nanjing 210009, China; 4Department of Endocrinology, Affiliated Hospital of Guilin Medical University, Guilin 541001, China

*These authors jointly supervised this work.

Correspondence to: Chunlin Ou. Department of Pathology, Xiangya Hospital, Central South University, Changsha 410008, China. Email:; Suxian Zhou. Department of Endocrinology, Xiangya Hospital, Central South University, Changsha 410008, China. Email:

Provenance: This is an invited editorial commissioned by Section Editor Dr. Chunlin Ou, MD, PhD (Cancer Research Institute of Central South University, Changsha, China).

Comment on: Sun SF, Tang PM, Feng M, et al. Novel lncRNA Erbb4-IR promotes diabetic kidney injury in db/db mice by Targeting miR-29b. Diabetes 2018;67:731-44.

Submitted Feb 26, 2018. Accepted for publication Feb 27, 2018.

doi: 10.21037/tcr.2018.03.07

With the acceleration of global aging, the incidence of diabetes mellitus (DM) is significantly increasing and is accompanied by a significant increase in the incidence of diabetic nephropathy (DN), a major complication of diabetes. DN is the leading cause of end-stage renal disease (ESRD) in DM, with a prevalence of 20–40%, and is the major cause of death and disability in DM patients (1). DN is characterized by progressive renal interstitial fibrosis (2), leading to a series of pathological changes, including mesangial expansion and mesangial matrix overproduction, and excessive thickening of tubular basement membranes and extracellular matrix (ECM) accumulation in glomerular (3). Moreover, the progress of DM is involving in various signaling pathways, including the nuclear factor-kappa B pathway (4), Hippo pathway (5), and the transforming growth factor-beta (TGFβ) pathway (6). In the past few decades, the diagnosis and treatment of DN has improved. However, it is still very difficult to distinctly reduce the mortality of this population (7,8). Therefore, an effective treatment to improve the long-term survival of DN patients is urgently needed.

Non-coding RNAs (ncRNAs) include microRNAs (miRNAs) (9), circular RNA (cicrcRNA) (10), and long non-coding RNA (lncRNA) (11). LncRNAs were firstly discovered in eukaryotes. The length of the lncRNA transcript exceeds 200 nucleotides (12). The possible origins of lncRNAs include insertion transposable elements, gene mutations, tandem duplication events, chromatin rearrangement, and retrotransposition (13). Moreover, lncRNAs can be divided into five categories depended on their proximity to the genomes of neighbouring transcripts: intronic synthesis, sense strand synthesis, antisense strand synthesis, intergenic synthesis (lincRNAs), and bidirectional synthesis (14,15). Although lncRNAs do not translate into functional proteins, they act as pivotal regulators in various biological processes mediated by RNA or functional short peptides (16). LncRNAs play a vital role in the occurrence and development of DN, and regulate ECM accumulation to promote renal fibrosis. Thomas et al. (17) found that lncRNA ANRIL (also known as CDKN2B-AS1) promotes kidney injury by improving the expression of fibronectin (FN) and type IV collagen (Col1α4). Zhang et al. (18) revealed that plasmacytoma variant translocation 1 (PVT1) is closely associated with TGF-β and c-myc expression, that the overexpression of PVT1 is accompanied by increases in TGF-β and c-myc expression, and that PVT1 overexpression enhances ECM accumulation. Interestingly, an RNA sequencing study revealed details of the lncRNA gene transcriptome and the dynamic and time-dependent function of proximal tubular cells in mice (19). The findings should inform lncRNA-based diagnosis and therapies for DN.

A recently published article in Diabetes by Sun et al. (20) has provided a novel insight about the relationship between Smad3-dependent lncRNA Erbb4-IR and type-2 DN (T2DN) in db/db mice. In this study, the authors identified that Erbb4-IR is markedly upregulated in T2DN induced by advanced glycation end product rather than high glucose via a Smad3-dependent mechanism, because deletion of Smad3 but not Smad2 was blocked. Furthermore, they used kidney-specific silencing of Erbb4-IR of db/db mice to study the function of Erbb4-IR in DN, and demonstrated the markedly increased expression of miR-29b by the silencing of Erbb4-IR in vivo and in vitro. The collective results of the study revealed that Erbb4-IR promotes renal fibrosis in T2DN by suppressing miR-29b, and that the Erbb4-IR-miR-29b axis is a key mechanism in kidney injury during the progression of DN. These findings may provide a novel therapy for T2DN. However, I have three issues concerning this article. First, the authors reported that the db/m or db/db mice were treated at 12, 15, and 18 weeks of age with the vector containing shRNA sequence targeting Erbb4-IR (Erbb4-IR-shRNA-pSuper.puro), and were sacrificed at week 20. I am not sure that whether the effect of shRNA vector in, in vivo experiments can be maintained for two months. A protracted lncRNA silencing is usually achieved by constructing lentivirus stably silenced cell lines or crispr/cas9 knockout cell lines in vivo. Secondly, miRNAs genes are first transcribed into polyadenylated primary transcripts (pri-miRNAs), which are cleaved by the Drosha ribonuclease III enzyme to produce an approximately 70-nt stem-loop precursor miRNA (pre-miRNA), At this point, pre-miRNA does not have a 3'UTR. Therefore, with regard to Figure 8A, I am very confused about the targeted binding of lncRNA Erbb4-IR to the 3'UTR region of pri-miR-29b. If the conclusion is tenable, then the biological process is bound to occur in the nucleus. However, Figure S7 shows that lncRNA Erbb4-IR is mainly located in the cytoplasm. The findings seem contradictory. In addition, the expression of pri-mir-29b and pre-mir-29b should be further examined to determine the role of lncRNA Erbb4-IR in the process of miR-29b production. Thirdly, miR-29b seems inappropriate in this study, since it only vaguely explains lncRNA Erbb4-IR through miR-29b regulation of renal injury in db/db mice. Does kidney-specific silencing of miR-29b really inhibit renal injury in db/db mice?

In summary, Sun et al. (20) clearly establish the regulatory mechanism of the novel lncRNA Erbb4-IR in the model of db/db mice, and provide a therapeutic target for DN patients. Increasingly more lncRNAs are being discovered and described with the development of RNA-seq and next generation sequencing technologies. LncRNAs are very stable in disease-related tissues, cells, and serum because of their unique structure. In addition, compared with protein detection, lncRNA extraction and detection have higher specificity, sensitivity, and stability compared with miRNAs. Thus, lncRNAs have become the new biomarkers of diagnosis and are therapeutic targets for DM. Recently, there are two notable challenges to lncRNA research. First, the lncRNA sequences need to be verified in human cells or tissues to prove whether it is functional. Second, functional lncRNAs need to be further investigated to determine if they are specifically related to one or more diseases and to explore the underlying molecular mechanisms of these associations. Consequently, there is an urgent need for further research to support clinical applications (21). Although our existing understanding of lncRNAs is just the tip of the iceberg, novel approaches and techniques will ultimately shed light on these processes and provide a new strategy for the early diagnosis, prevention, and treatment of DM.


Funding: This work was supported by the Natural Science Foundation of China (No. 81260134, 81560148), and the Student Innovation Project of Central South University (No. 2017zzts010).


Conflicts of Interest: The authors have no conflicts of interest to declare.


  1. Ninomiya H, Katakami N, Matsuoka TA, et al. Association beween poor psychosocial conditions and diabetic nephropathy in Japanese type 2 diabetes patients: A cross-sectional study. J Diabetes Investig 2018;9:162-72. [Crossref] [PubMed]
  2. Valk EJ, Bruijn JA, Bajema IM. Diabetic nephropathy in humans: pathologic diversity. Curr Opin Nephrol Hypertens 2011;20:285-9. [Crossref] [PubMed]
  3. Abe H. Recent progress in understanding the molecular pathogenesis of diabetic nephropathy. Rinsho Byori 2011;59:179-86. [PubMed]
  4. Ou C, Sun Z, Zhang H, et al. SPLUNC1 reduces the inflammatory response of nasopharyngeal carcinoma cells infected with the EB virus by inhibiting the TLR9/NF-kappaB pathway. Oncol Rep 2015;33:2779-88. [Crossref] [PubMed]
  5. Ou C, Sun Z, Li S, et al. Dual roles of yes-associated protein (YAP) in colorectal cancer. Oncotarget 2017;8:75727-41. [Crossref] [PubMed]
  6. Zhou SX, Huo DM, He XY, et al. High glucose/lysophosphatidylcholine levels stimulate extracellular matrix deposition in diabetic nephropathy via plateletactivating factor receptor. Mol Med Rep 2018;17:2366-72. [PubMed]
  7. Parving HH, Brenner BM, Mcmurray JJ, et al. Cardiorenal end points in a trial of aliskiren for type 2 diabetes. N Engl J Med 2012;367:2204-13. [Crossref] [PubMed]
  8. Cooper ME. Diabetes: treating diabetic nephropathy-still an unresolved issue. Nat Rev Endocrinol 2012;8:515-6. [Crossref] [PubMed]
  9. Ou C, Sun Z, Li X, et al. MiR-590-5p, a density-sensitive microRNA, inhibits tumorigenesis by targeting YAP1 in colorectal cancer. Cancer Lett 2017;399:53-63. [Crossref] [PubMed]
  10. He X, Kuang G, Ou C, et al. Crosstalk between circular RNAs and microRNAs in tumorigenesis. Transl Cancer Res 2017;6:S1448-50. [Crossref]
  11. Murugan AK, Munirajan AK, Alzahrani AS. Long noncoding RNAs: emerging players in thyroid cancer pathogenesis. Endocr Relat Cancer 2018;25:R59-82. [Crossref] [PubMed]
  12. He X, Ou C, Xiao Y, et al. LncRNAs: key players and novel insights into diabetes mellitus. Oncotarget 2017;8:71325-41. [PubMed]
  13. Ponting CP, Oliver PL, Reik W. Evolution and functions of long noncoding RNAs. Cell 2009;136:629-41. [Crossref] [PubMed]
  14. Gutschner T, Diederichs S. The hallmarks of cancer: a long non-coding RNA point of view. RNA Biol 2012;9:703-19. [Crossref] [PubMed]
  15. He Y, Meng XM, Huang C, et al. Long noncoding RNAs: Novel insights into hepatocellular carcinoma. Cancer Lett 2014;344:20-7. [Crossref] [PubMed]
  16. Ou C, Li G. Long non-coding RNA TUG1: a novel therapeutic target in small cell lung cancer. J Thorac Dis 2017;9:E644-5. [Crossref] [PubMed]
  17. Thomas AA, Feng B, Chakrabarti S. ANRIL regulates production of extracellular matrix proteins and vasoactive factors in Diabetic Complications. Am J Physiol Endocrinol Metab 2018;314:E191-200. [Crossref] [PubMed]
  18. Zhang R, Li J, Huang T, et al. Danggui buxue tang suppresses high glucose-induced proliferation and extracellular matrix accumulation of mesangial cells via inhibiting lncRNA PVT1. Am J Transl Res 2017;9:3732-40. [PubMed]
  19. Tang W, Zhang D, Ma X. RNA-sequencing reveals genome-wide long non-coding RNAs profiling associated with early development of diabetic nephropathy. Oncotarget 2017;8:105832-47. [Crossref] [PubMed]
  20. Sun SF, Tang PM, Feng M, et al. Novel lncRNA Erbb4-IR promotes diabetic kidney injury in db/db Mice by Targeting miR-29b. Diabetes 2018;67:731-44. [Crossref] [PubMed]
  21. He X, Ou C. Exosome-derived microRNAs in cancer progression: angel or devil? J Thorac Dis 2017;9:3440-2. [Crossref] [PubMed]
Cite this article as: He X, Pu C, Ou C, Zhou S. The emerging landscape of lncRNAs in diabetic nephropathy. Transl Cancer Res 2018;7(Suppl 4):S463-S465. doi: 10.21037/tcr.2018.03.07